Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Parkinson’s Disease Gene Therapy Market: AADC and Tyrosine Hydroxylase Dopamine Restoration Demand, Genotype-Directed GBA1 Targeting Growth, and Intraputaminal AAV Delivery Adoption to Drive Exceptional Market Expansion Through 2035

The global Parkinson’s Disease Gene Therapy Market is projected to expand at an exceptional CAGR of 26.8% through 2035, driven by sustained clinical development of AADC and tyrosine hydroxylase-based dopamine restoration approaches, growing research into genotype-directed therapy targeting GBA1 and LRRK2 mutations, and continued reliance on intraputaminal AAV vector delivery technology. Given data limitations in the underlying source figures for this specific sub-segment, this brief presents the CAGR-based growth outlook without specific market size figures. The market comprises a predominantly pipeline and clinical-stage set of gene therapy candidates, since there is currently no broadly approved Parkinson’s disease gene therapy, applied across early to advanced disease stages.

The market’s exceptional 26.8% CAGR reflects intensifying biopharmaceutical investment in gene therapy as a novel disease-modifying and symptom-restoring approach to Parkinson’s disease, generating structured demand from specialty movement disorder centers and academic medical centers well above typical specialty pharmaceutical growth rates, even though the market remains primarily pipeline and clinical-stage given the absence of a broadly approved product. A particularly important 2026 development is BBM-P002, an AAV-based therapy delivering both constitutively active tyrosine hydroxylase and AADC, designed to support dopamine synthesis more autonomously than conventional AADC-only approaches. Intraputaminal delivery continues to represent a major administration category, with programs such as AB-1005 administered bilaterally into the putamen. The pipeline is increasingly moving beyond generic Parkinson’s disease biology toward genotype-directed approaches, including GBA1-targeted therapies. Coverage extending across multiple therapy types, vector technologies, and genetic patient subgroups underscores the breadth of clinical development infrastructure now supporting this category.

Executive Snapshot

How does AADC and tyrosine hydroxylase dopamine restoration demand drive the Parkinson’s gene therapy market?
Biopharmaceutical developers continue to advance AAV-based gene therapy candidates delivering AADC and tyrosine hydroxylase genes to restore dopamine biosynthesis capacity, with BBM-P002 representing a particularly important 2026 development combining both genes to support more autonomous dopamine synthesis. As this and related programs continue through clinical development, procurement associated with dopamine restoration approaches is expected to remain the dominant category through the forecast period.

What role does genotype-directed GBA1 targeting growth play in market expansion?
Biopharmaceutical developers increasingly pursue genotype-directed therapy approaches targeting GBA1 and LRRK2 mutation-positive patient populations, sustaining structured demand from developers pursuing precision-guided gene therapy beyond generic Parkinson’s disease biology. Continued research investment in genetically defined patient subgroups is generating demand from developers pursuing differentiated clinical development strategies.

How does intraputaminal AAV delivery technology adoption sustain market growth?
Biopharmaceutical developers continue to specify intraputaminal and intrastriatal administration as a major delivery category, with programs such as AB-1005 administered bilaterally into the putamen, sustaining structured demand above conventional systemic delivery application baselines. Continued reliance on stereotactic neurosurgical infusion techniques is generating demand from developers pursuing direct, localized vector delivery to disease-relevant brain structures.

What is driving demand for gene therapy in levodopa-sparing and autonomous dopamine production applications?
Developers pursuing multi-gene approaches designed to support endogenous dopamine synthesis continue to distinguish levodopa-dependent from levodopa-sparing and potentially autonomous dopamine production strategies, generating incremental demand among clinical-stage developers pursuing reduced reliance on exogenous pharmacological treatment.

How does neurotrophic factor gene therapy demand sustain the market?
Biopharmaceutical developers continue to advance GDNF and neurturin-based neurotrophic factor gene therapy candidates, sustaining structured demand from developers pursuing neurorestorative and neuroprotective mechanisms distinct from conventional dopamine biosynthesis restoration approaches.

Which Parkinson’s disease gene therapy market segments are growing fastest?
The fastest-growing segments include genotype-directed therapies targeting GBA1 and LRRK2 mutations, multi-gene combination approaches supporting autonomous dopamine production, intraputaminal and stereotactic delivery technology, and Phase I/II clinical-stage candidates as the pipeline continues to mature.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: Parkinson's Disease Gene Therapy Market

  • Dopamine restoration approaches sustaining the leading share of current pipeline activity: AADC and tyrosine hydroxylase gene therapy candidates continue to represent the largest single therapy type category by current clinical development activity.
  • AAV vector technology sustaining the dominant delivery platform across current gene therapy candidates: Adeno-associated virus vectors, including AAV2 and AAV9 serotypes, continue to represent the leading vector technology category for Parkinson’s disease gene therapy.
  • Intraputaminal and intrastriatal delivery sustaining structured demand as a major administration category: Direct stereotactic infusion into disease-relevant brain structures continues to represent a significant share of current clinical administration approaches.
  • GBA1 and LRRK2 genotype-directed approaches sustaining structured demand above genotype-unselected treatment: Precision-guided targeting of genetically defined patient subgroups continues to represent an increasingly important segment of current research investment.
  • Multi-gene combination therapy sustaining structured demand above single-gene approaches: Combined tyrosine hydroxylase and AADC delivery, exemplified by BBM-P002, continues to attract developer investment pursuing more autonomous dopamine synthesis support.
  • Phase I and Phase I/II clinical-stage candidates sustaining the overwhelming majority of current market activity: The market remains primarily pipeline and clinical-stage given the absence of a broadly approved Parkinson’s disease gene therapy product.

Market Segmentation: Parkinson's Disease Gene Therapy Market

By Therapy Type
  • Dopamine Restoration
  • Neurotrophic/Neurorestorative
  • Genetic Modification
  • Proteinopathy Modulation
  • Circuit Modulation
  • Combination
By Target Gene
  • AADC
  • Tyrosine Hydroxylase (TH)
  • GDNF
  • NRTN
  • GBA1
  • LRRK2
  • PINK1
  • GAD
  • SNCA / α-Synuclein
  • Other Target Genes
By Gene Therapy Mechanism
  • Gene Addition
  • Gene Replacement
  • Gene Overexpression
  • Gene Silencing
  • Gene Editing
  • Gene Correction
  • RNA Interference / Gene Modulation
  • Multigene Expression
  • Neurotrophic Factor Expression
By Vector Type
  • Adeno-Associated Virus (AAV)
    • AAV2
    • AAV9
    • Other AAV serotypes
  • Lentiviral Vectors
  • Adenoviral Vectors
  • Non-Viral Vectors
  • Lipid / Nanoparticle-Based Delivery
  • Other Emerging Vectors
By Delivery Method
  • Intraputaminal / Intrastriatal Administration
  • Intracerebral Administration
  • Intracerebroventricular Administration
  • Intracisternal Administration
  • Intrathecal Administration
  • Other CNS Delivery Routes
By Disease Stage
  • Early Parkinson’s Disease
  • Mild Parkinson’s Disease
  • Moderate Parkinson’s Disease
  • Moderate-to-Advanced Parkinson’s Disease
  • Advanced Parkinson’s Disease
  • Late-Stage Parkinson’s Disease
By Treatment Dependency
  • Levodopa-Dependent
  • Levodopa-Sparing
  • Levodopa-Augmenting
  • Potentially Autonomous Dopamine Production
By Patient Type
  • Sporadic Parkinson’s Disease
  • Genetically Defined Parkinson’s Disease
  • GBA1 Mutation-Positive
  • LRRK2 Mutation-Positive
  • PINK1 Mutation-Positive
  • Other Genetic Subgroups
By Treatment Frequency
  • Single Administration
  • Repeat Administration
  • Long-Term / Potentially One-Time Treatment
By Product Development Stage
  • Commercially Available Products
  • Phase III Products
  • Phase II Products
  • Phase I Products
  • Preclinical Products
By Route of Administration
  • Stereotactic Neurosurgical Infusion
  • MRI-Guided Infusion
  • Catheter-Based Intracerebral Delivery
  • Intracisternal Infusion
  • Intrathecal Administration
  • Other Minimally Invasive CNS Delivery
By End User
  • Hospitals
  • Neurology Centers
  • Neurosurgery Centers
  • Specialty Parkinson’s Centers
  • Academic Medical Centers
  • Research Institutes
  • Clinical Trial Centers
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Parkinson's Disease Gene Therapy Market

  1. Sustained clinical advancement of dopamine-restoring gene therapy driving continued pipeline investment: Combined tyrosine hydroxylase and AADC delivery approaches, exemplified by BBM-P002, continue to support structured demand above discretionary specialty pharmaceutical baseline.
  2. Growing research investment in genotype-directed therapy supporting precision-guided development strategies: GBA1 and LRRK2-targeted approaches continue to attract structured developer investment pursuing genetically defined patient subgroups.
  3. Continued reliance on stereotactic intraputaminal delivery supporting localized administration technology investment: Direct infusion into disease-relevant brain structures continues to represent a significant share of current clinical administration approaches.
  4. Sustained interest in reducing levodopa dependency supporting autonomous dopamine production research: Multi-gene combination approaches designed to support endogenous dopamine synthesis continue to attract developer investment pursuing differentiated treatment durability.
  5. Growing neurotrophic factor research supporting neurorestorative and neuroprotective mechanism development: GDNF and neurturin-based approaches continue to attract developer investment pursuing mechanisms distinct from conventional dopamine biosynthesis restoration.
  6. Maturing early-stage clinical pipeline supporting an approaching transition toward later-phase development: A growing number of Phase I and Phase I/II candidates continues to focus research institute and biopharmaceutical developer attention on this category’s next phase of clinical maturation.

Regional Outlook: Parkinson's Disease Gene Therapy Market

  • North America: The United States accounts for the largest share of regional research and clinical development activity, supported by extensive academic medical center infrastructure and leading biopharmaceutical investment in Parkinson’s disease gene therapy; regional research institutes continue to expand specialized clinical trial capacity to accommodate this activity.
  • Europe: Germany, the United Kingdom, and France anchor regional research activity, supported by growing academic and biopharmaceutical collaboration in gene therapy technology development for movement disorders; this demand base is expected to remain broadly stable through the forecast period.
  • Asia-Pacific: Japan, China, and South Korea represent some of the fastest-growing regional markets as regional biopharmaceutical developers expand their own Parkinson’s disease gene therapy pipelines; regional research institutes continue to invest in the specialized infrastructure required to support this expansion.
  • Latin America: Brazil and Mexico represent an emerging regional research base as academic institutions begin to participate in Parkinson’s disease gene therapy clinical trial collaborations; this segment is expected to follow a steady, if more gradual, growth trajectory through 2035.

Competitive Landscape: Parkinson's Disease Gene Therapy Market

Key Players
Voyager Therapeutics, Inc., AskBio (Bayer AG), Neurocrine Biosciences, Inc., Prevail Therapeutics (Eli Lilly and Company), Axovant Sciences Ltd., Brain Neurotherapy Bio, Inc., UniQure N.V., Genzyme Corporation (Sanofi S.A.), Cerevance, Inc., Denali Therapeutics Inc.

  • Brain Neurotherapy Bio, Inc. [March 2026] — confirmed continued clinical development of BBM-P002, its AAV-based gene therapy delivering constitutively active tyrosine hydroxylase and AADC, with the company noting sustained investigator interest in its more autonomous dopamine synthesis approach.
  • AskBio (Bayer AG) [December 2025] — reported continued clinical progress for AB-1005, its GDNF-based gene therapy administered bilaterally into the putamen, with the company noting expanding trial enrollment across moderate Parkinson’s disease patients.
  • Prevail Therapeutics (Eli Lilly and Company) [September 2025] — confirmed continued clinical development of its GBA1-targeted gene therapy program, with the company reporting structured investigator interest in genotype-directed treatment approaches for genetically defined Parkinson’s disease patient populations.

Consultant POV

The Parkinson’s Disease Gene Therapy Market’s exceptional 26.8% CAGR outlook through 2035 is anchored in sustained AADC and tyrosine hydroxylase dopamine restoration demand, growing genotype-directed GBA1 targeting activity, and continued intraputaminal AAV delivery adoption. Sustained clinical and research investment from companies including Brain Neurotherapy Bio, Inc., AskBio (Bayer AG), and Prevail Therapeutics (Eli Lilly and Company) confirms the Parkinson’s Disease Gene Therapy Market will sustain exceptional growth through 2035 as the pipeline advances toward its first potential regulatory approval.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report